Floatz logo

Pembrolizumab

Gliosarcoma

Explore 48 assets in Gliosarcoma →
Floatz Rating
B60/100
Confidence
Indicative
v0.2
Sponsor
Mayo Clinic
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT07301268CT.gov
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
—Recruiting———
NCT05465954CT.gov
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
—Recruiting———
NCT05084430CT.gov
Study of Pembrolizumab and M032 (NSC 733972)
—Recruiting———
NCT03197506CT.gov
Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma
—Active Not Recruiting———
NCT02798406CT.gov
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
—Completed———
NCT02337686CT.gov
Pembrolizumab in Treating Patients With Recurrent Glioblastoma
—Active Not Recruiting———
NCT01814813CT.gov
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
—Terminated———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Gliosarcoma

AssetSponsorPhaseRating
Pembrolizumab (this asset)Mayo ClinicP2B · 60
CediranibNorthwestern UniversityP2BBB
TemsirolimusNational Cancer Institute (NCI)P2BBB
SorafenibUniversity Hospital, GenevaP2BB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-National Cancer Institute (NCI)P2BB
GefitinibNational Cancer Institute (NCI)P2BB
TandutinibNational Cancer Institute (NCI)P2BB
VorinostatNational Cancer Institute (NCI)P2BB
IrinotecanRTOG Foundation, Inc.P3BB

+42 more in the Gliosarcoma cohort

Other indications for Pembrolizumab

IndicationSponsorPhaseRating
Her2-Receptor Negative Breast Cancer—P2BBB · 72
Estrogen-Receptor Negative Breast Cancer—P2BB · 71
Progesterone-Receptor Negative Breast Cancer—P2BB · 71

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Pembrolizumab in Gliosarcoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/pembrolizumab-gliosarcoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →